Loading
LC
Liquidia Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Sept 2024.
Liquidia Corp: what insiders have been doing
Liquidia Corp belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 21 insiders have disclosed 208 filings since 18 October 2025.
No insider bought on the market over the period, while 12 insiders filed 106 sales totalling €76.3M. No amount is published for 21 filings, which the totals therefore leave out. Biggest ticket of the year: €7.5M, sold by Bloch Stephen M and made public on 24 July 2026 (0.14% of market cap).
Compared with its exchange (5,812 companies, median 19 filings), a count of 208 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 21 purchases and 167 sales. The 10-K for the year ended 31 December 2025 shows 158.3 m USD of revenue and -68.9 m USD of net income.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
417
Thresholds
n/a
Buy Volume
€26M
21 ops. · all time
Sell Volume
€85M
167 ops. · all time
Who traded when
BuySaleStephen M. Bloch40 sales
Jason Adair22 sales
Dana Boyle16 sales
Rajeev Saggar12 sales
Roger Jeffs11 sales
Sarah Krepp10 sales
+8 other insiders
Since the insiders bought
- +155.6%Entry US$9.78 · Close at T+365 US$25.00
- +35.5%Entry US$7.89 · Close at T+365 US$10.69
- +48.1%Entry US$7.45 · Close at T+365 US$11.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Liquidia Corp Buy (bullish), based on 8 analysts. Average price target: US$53.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,840 of 24,148 companies
47.3
score / 100
Value28
Quality66
FCF yld-1.4%
Earn yld-2.2%
EV/EBITDA·
ROE132%
Gross mgn92%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$33.94
Analyst consensus
8 analystsBuy
US$33.00Target US$53.50(+58%)US$70.00
Income statement
RevenueUS$158.3M
Gross profitUS$145.1M92% margin
EBITDA-US$43.2M-27% margin
Net income-US$68.9M30.7% margin
Valuation
PER (trailing)19.3x
PER (forward)15.5x
P/Book15.5x
Beta0.61
Balance sheet & cash
Market capUS$3B
Total debtUS$197.9M
Free Cash Flow-US$42M
Debt / Equity94%
Profitability & ownership
ROE131.8%
ROA27.0%
% insiders9.2%
% institutions81.9%
Last declaration on 13 October 2026
Declarations417 total
3,758 sharesCommon StockSEC:0001104659-26-115650:0
6,409 sharesCommon StockSEC:0001104659-26-115650:1
3,530 sharesCommon StockSEC:0001104659-26-115649:0
4,486 sharesCommon StockSEC:0001104659-26-115649:1
3,108 sharesCommon StockSEC:0001104659-26-115648:0
4,358 sharesCommon StockSEC:0001104659-26-115648:1
5,828 sharesCommon StockSEC:0001104659-26-115644:0
13,833 sharesCommon StockSEC:0001104659-26-115642:0
14,333 sharesCommon StockSEC:0001104659-26-115642:1
3,178 sharesCommon StockSEC:0001104659-26-115641:0
3,868 sharesCommon StockSEC:0001104659-26-115640:2
5,245 shares@ US$28.480.0024% mcap10.5% of flowCommon StockSEC:0001104659-26-115647:1
13,692 shares@ US$28.480.0061% mcap21.8% of flowCommon StockSEC:0001104659-26-115650:2
9,218 shares@ US$28.480.0041% mcap2.8% of flowCommon StockSEC:0001104659-26-115649:2
8,863 shares@ US$28.480.0040% mcap20.8% of flowCommon StockSEC:0001104659-26-115648:2
3,178 sharesCommon StockSEC:0001104659-26-115647:0
1,101 shares@ US$28.480.0005% mcap27.3% of flowCommon StockSEC:0001104659-26-115646:0
7,049 sharesCommon StockSEC:0001104659-26-115644:1
18,938 shares@ US$28.480.0085% mcap6.0% of flowCommon StockSEC:0001104659-26-115644:2
32,744 shares@ US$28.480.015% mcap7.9% of flowCommon StockSEC:0001104659-26-115642:2
5,892 shares@ US$28.480.0026% mcap8.5% of flowCommon StockSEC:0001104659-26-115641:1
3,906 sharesCommon StockSEC:0001104659-26-115640:0
2,474 sharesCommon StockSEC:0001104659-26-115640:1
7,301 shares@ US$28.480.0033% mcap2.6% of flowCommon StockSEC:0001104659-26-115640:3
235,477 shares@ US$27.12620.10% mcap14.7% of flowCommon StockSEC:0001104659-26-114372:0
25 of 417 declarations
About Liquidia Corp
Liquidia Corp (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, focused on difficult-to-treat respiratory and vascular diseases. For investors, the key takeaway is that Liquidia is no longer a purely pre-commercial research story: it has crossed into commercialization with an approved and marketed product, while still retaining a development pipeline built around its proprietary PRINT® technology, designed to engineer precise particles. That technology remains central to the equity case because it supports formulation, drug delivery, and potentially broader future applications.
The company’s roots trace back to Liquidia Technologies, its wholly owned subsidiary and predecessor for SEC reporting purposes, before the business evolved into a commercial specialty biopharma platform. Liquidia is headquartered in Morrisville, North Carolina, in the Research Triangle area, one of the most established life-science clusters in the United States. That location provides access to talent, manufacturing and development infrastructure, and a broader ecosystem of scientific partners and service providers.
Read moreShow less
Liquidia’s core business today is anchored by YUTREPIA® (treprostinil) inhalation powder, a therapy approved for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company is developing L606, an investigational extended-release formulation of treprostinil intended for twice-daily administration with a next-generation nebulizer. Liquidia also states that it commercializes generic treprostinil injection for PAH. This combination of a marketed product, a development asset, and a complementary commercial franchise gives the company a more diversified profile than a single-asset biotech, although execution risk remains material.
From a competitive standpoint, Liquidia operates in a niche but highly regulated specialty market, where clinical differentiation, device/formulation expertise, and regulatory execution matter more than broad scale. Its competitive edge lies in precision-engineered inhalation therapy and the ability to translate a proprietary particle-engineering platform into real-world commercial uptake. Recent company disclosures indicate that YUTREPIA is gaining traction commercially, with full-year 2025 net product sales of about $148.3 million and roughly $130 million in first-quarter 2026 net product sales, underscoring that the business is now meaningfully commercial. The company has also issued several investor updates and conference participation announcements in spring 2026, and recent Form 4 filings reflect insider transactions, including share sales and award-related activity, which investors should view in context rather than in isolation.
Overall, Liquidia is a NASDAQ-listed U.S. healthcare name that sits between a growth-stage specialty pharma company and a commercially established rare-disease player. The story combines a proprietary technology base, a newly scaled commercial product, and a pipeline that could extend the franchise, but it also remains exposed to reimbursement, execution, and competitive risks typical of specialty biopharma.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
